Latest Breaking News On - ஜெஃப்ரி விடுவிக்கப்பட்டவர் - Page 7 : comparemela.com
AB Science communicates the results from phase 2B/3 study evaluating masitinib in Alzheimer s disease – IT Business Net
itbusinessnet.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from itbusinessnet.com Daily Mail and Mail on Sunday newspapers.
AB Science issues a corrective press release regarding adverse events information from study AB09004 reported on December 16, 2020
globenewswire.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from globenewswire.com Daily Mail and Mail on Sunday newspapers.
Share:
PHASE 2B/3 STUDY EVALUATING MASITINIB IN ALZHEIMER S DISEASE MET ITS PRIMARY ENDPOINT
MASITINIB DEMONSTRATED SIGNIFICANT EFFECT ON BOTH COGNITION, MEASURED WITH ADAS-COG, AND DAILY ACTIVITY, MEASURED WITH ADCS-ADL
AB SCIENCE WILL HOST A LIVE WEBCAST ON DECEMBER 17, 2020 - 11am-12am EST; 5pm-6pm CET WITH KEY OPINION LEADERS TO FURTHER DISCUSS THE RESULTS
Paris, December 16, 2020, 8am CET
AB Science SA (Euronext - FR0010557264 - AB) today announced that the Phase 2B/3 study (AB09004 - NCT01872598) evaluating oral masitinib in patients with mild and moderate Alzheimer s disease met its predefined primary endpoint.
Study AB09004 was an international, randomized, placebo-controlled, phase 2B/3 study evaluating different doses of masitinib as a treatment of patients with confirmed mild to moderate Alzheimer s disease. This study compared the efficacy and safety of masitinib relative to placebo after 24 weeks of treatment when administered as an add-on therapy to cholinesterase
PHASE 2B/3 STUDY EVALUATING MASITINIB IN ALZHEIMER’S DISEASE MET ITS PRIMARY ENDPOINT
MASITINIB DEMONSTRATED SIGNIFICANT EFFECT ON BOTH COGNITION, MEASURED WITH ADAS-COG, AND DAILY ACTIVITY, MEASURED WITH ADCS-ADL
AB SCIENCE WILL HOST A LIVE WEBCAST ON DECEMBER 17, 2020 - 11am-12am EST; 5pm-6pm CET WITH KEY OPINION LEADERS TO FURTHER DISCUSS THE RESULTS
Paris, December 16, 2020, 8am CET
AB Science SA (Euronext - FR0010557264 - AB) today announced that the Phase 2B/3 study (AB09004 - NCT01872598) evaluating oral masitinib in patients with mild and moderate Alzheimer’s disease met its predefined primary endpoint.
Study AB09004 was an international, randomized, placebo-controlled, phase 2B/3 study evaluating different doses of masitinib as a treatment of patients with confirmed mild to moderate Alzheimer’s disease. This study compared the efficacy and safety of masitinib relative to placebo after 24 weeks of treatment when administered as an add-on therapy to cholinesterase i
AB Science announces that Phase 2B/3 study evaluating oral in Alzheimer s disease met its primary endpoint – IT Business Net
itbusinessnet.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from itbusinessnet.com Daily Mail and Mail on Sunday newspapers.